Iovance Biotherapeutics stock hits 52-week high at 9.36 USD

Iovance Biotherapeutics Inc.'s stock surged to a 52-week high of $9.36, signifying a major achievement for the company. Trading at $9.38, the stock boasts a substantial market capitalization of $4.2 billion. The year-to-date performance has been impressive, delivering a 215% return and a nearly 279% gain over the past year, signaling robust investor confidence and promising prospects within the biotherapeutics sector.

However, InvestingPro analysis suggests the stock may be overvalued compared to its Fair Value, a point investors can further explore on the Most Overvalued stocks list. This sharp increase in stock value highlights the company's progress and strategic moves, solidifying its position as a significant player in the industry. For additional insights, investors can consult InvestingPro, which provides 10 exclusive tips and a detailed Pro Research Report on IOVA and 1,400+ other US equities.

Recently, Iovance Biotherapeutics exceeded Wall Street's expectations in its second-quarter 2026 results. The company reported a record revenue of $99.31 million, well surpassing the projected $87.12 million, thanks to strong sales of its leading cancer therapy, Amtagvi. Adjusted earnings improved to a narrower loss of $0.11 per share compared to the estimated $0.13 loss.

UBS upgraded its price target for Iovance Biotherapeutics from $4.00 to $7.00, maintaining a Neutral rating, as the company's quarterly revenue surpassed forecasts with Amtagvi generating $91 million. Proleukin contributed $9 million in revenue, slightly above the consensus estimate. Additionally, TD Cowen raised its price target from $7.00 to $10.00 while keeping a Buy rating, updating its Amtagvi sales projections to $95 million for the third quarter and $99 million for the fourth quarter.

These developments underscore the company's strong performance and a positive outlook from analysts. This report was generated with AI assistance and reviewed by an editor for accuracy.